Business Description
Salarius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US33938A1051
Description
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.35 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.3 | |||||
| 3-Year EPS without NRI Growth Rate | 33.3 | |||||
| 3-Year FCF Growth Rate | 38.1 | |||||
| 3-Year Book Growth Rate | -61.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.14 | |||||
| 9-Day RSI | 50.23 | |||||
| 14-Day RSI | 47.13 | |||||
| 6-1 Month Momentum % | -15.18 | |||||
| 12-1 Month Momentum % | -64.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.02 | |||||
| Quick Ratio | 5.02 | |||||
| Cash Ratio | 4.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -60.5 | |||||
| Shareholder Yield % | -284.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -175.53 | |||||
| ROA % | -121.18 | |||||
| ROIC % | -5195.41 | |||||
| ROCE % | -180.46 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.38 | |||||
| Price-to-Tangible-Book | 0.38 | |||||
| EV-to-EBIT | 0.25 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-FCF | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 0.38 | |||||
| Price-to-Net-Cash | 0.43 | |||||
| Earnings Yield (Greenblatt) % | 400 | |||||
| FCF Yield % | -529.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Salarius Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.31 | ||
| Beta | 0.2 | ||
| Volatility % | 66.09 | ||
| 14-Day RSI | 47.13 | ||
| 14-Day ATR ($) | 0.055203 | ||
| 20-Day SMA ($) | 0.493663 | ||
| 12-1 Month Momentum % | -64.16 | ||
| 52-Week Range ($) | 0.43 - 2.31 | ||
| Shares Outstanding (Mil) | 4.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Salarius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Salarius Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Salarius Pharmaceuticals Inc Frequently Asked Questions
What is Salarius Pharmaceuticals Inc(SLRX)'s stock price today?
The current price of SLRX is $0.51. The 52 week high of SLRX is $2.31 and 52 week low is $0.43.
When is next earnings date of Salarius Pharmaceuticals Inc(SLRX)?
The next earnings date of Salarius Pharmaceuticals Inc(SLRX) is 2024-04-25.
Does Salarius Pharmaceuticals Inc(SLRX) pay dividends? If so, how much?
Salarius Pharmaceuticals Inc(SLRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers